Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Oct 2014 |
| Grant of Warrants to Genmab Employees | 15 Oct 2014 |
| Genmab to Present at the Bank of America Merrill Lynch Global Healthcare Conference 2014 | 11 Sept 2014 |
| Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration | 10 Sept 2014 |
| Genmab’s Total Number of Voting Rights and Total Share Capital | 29 Aug 2014 |